Gilead will begin providing Redsiewe to new coronavirus patients in areas with severe outbreaks this week.

A few weeks ago, a study in the New England Journal of Medicine showed that a significant proportion of new coronavirus patients showed signs of improvement when they were treated with Redcivir, a drug developed by Gilead that had previously been used to help treat Ebola patients. And the latest news from Gilead’s chief executive, Daniel O’Day, is that it will provide Redcivir to new coronavirus patients in areas with severe outbreaks.

Gilead will begin providing Redsiewe to new coronavirus patients in areas with severe outbreaks this week.

Speaking on CBS’ Face The Nation earlier Monday, Daniel O’Day said Gilead was planning to “get patients to use Ridsyway early this week.” The company has been working with the government to “determine which cities are the most vulnerable and which patients are in need of the drug.”

What’s more, O’Day said, Gilead will donate all of its drug supplies to help with the treatment of the new coronavirus. “We’ve donated all of our supply in our supply chain, and we’re doing so because we recognize and recognize human suffering, human needs here, and want to make sure nothing gets in the way of patients,” O’Day added.

While it remains to be seen how well Redciewe’s large-scale treatment will be, early clinical trials have yielded some encouraging results. The first trial involved 53 patients with new coronary severe disease. After a week of treatment, 36 of the 53 patients showed significant signs of clinical improvement. Although 12 patients experienced serious problems, it was not clear whether they were related to drugs or potential medical problems.

Part of the study is:

During the 18-day median follow-up period, the oxygen supply level improved in 36 patients (68%), of which 17 (57%) of the 30 patients who received mechanical ventilation had been removed. A total of 25 patients (47 per cent) were discharged and 7 patients (13 per cent) died, while patients receiving invasive ventilation had a mortality rate of 18 per cent (6 out of 34) and patients without invasive ventilation had a mortality rate of 5 per cent (1 out of 19).

A subsequent study involving 1,000 patients was equally encouraging.

Following the study, the FDA approved Redcievir as a new coronavirus treatment drug late last week through an Emergency Use Authorization (EAU).